Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 7, 2015; 21(45): 12954-12962
Published online Dec 7, 2015. doi: 10.3748/wjg.v21.i45.12954
Published online Dec 7, 2015. doi: 10.3748/wjg.v21.i45.12954
Hybrid therapy for Helicobacter pylori infection: A systemic review and meta-analysis
Ping-I Hsu, Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital and National Yang-Ming University, Kaohsiung 813, Taiwan
Pei-Chin Lin, Department of Pharmacy, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan
Pei-Chin Lin, College of Pharmacy, Kaohsiung Medical University, Kaohsiung 807, Taiwan
David Y Graham, Department of Medicine/Gastroenterology, Michael E. DeBakey Veterans Affairs Medical Center, and Baylor College of Medicine, Houston, TX 77030, United States
Author contributions: Hsu PI designed the study, reviewed the articles, analyzed the data and drafted the manuscript; Lin PC reviewed the articles and analyzed the data; and Graham DY designed the study and reviewed the manuscript.
Supported by Research Foundation of the Kaohsiung Veterans General Hospital, No. VGHKS103-58.
Conflict-of-interest statement: Hsu PI and Lin PC disclose no conflict of interest; Graham DY is an unpaid consultant for Novartis in relation to vaccine development for treatment or prevention of Helicobacter pylori (H. pylori) infection; Graham DY is also a paid consultant for RedHill Biopharma regarding novel H. pylori therapies and for Otsuka Pharmaceuticals regarding diagnostic testing; and Graham DY has received royalties from Baylor College of Medicine patents covering materials related to 13C-urea breath test.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: David Y Graham, Professor, Department of Medicine/Gastroenterology, Michael E. DeBakey Veterans Affairs Medical Center, and Baylor College of Medicine, Room 3A-320, 2002 Holcombe Blvd., Houston, TX 77030, United States. dgraham@bcm.tmc.edu
Telephone: +1-713-7950232 Fax: +1-713-7901040
Received: April 29, 2015
Peer-review started: May 12, 2015
First decision: July 19, 2015
Revised: August 7, 2015
Accepted: September 30, 2015
Article in press: September 30, 2015
Published online: December 7, 2015
Peer-review started: May 12, 2015
First decision: July 19, 2015
Revised: August 7, 2015
Accepted: September 30, 2015
Article in press: September 30, 2015
Published online: December 7, 2015
Core Tip
Core tip: This article is aimed to review current evidences of hybrid therapy for Helicobacter pylori infection. The mean cure rates of hybrid therapy by intention-to-treat and per-protocol analyses were 88.5% and 93.3%, respectively. Meta-analysis showed that hybrid therapy was more effective than sequential therapy in the non-Italian population. In contrast, it was less effective than sequential therapy in the Italian population. There was no significant difference in eradication rate between hybrid therapy and concomitant therapy. Reverse hybrid therapy is a new one-step tow-phase treatment, achieving a higher eradication rate than standard triple therapy with similar tolerability and less pharmaceutical cost.